Back

Long-read transcriptome analysis using IsoRanker for identifying pathogenic variants in Mendelian conditions

Cheng, Y.-H. H.; Sedeno-Cortes, A. E.; Ranchalis, J. E.; Munson, K. M.; Vollger, M. R.; Balton, E.; Genetti, C. A.; Undiagnosed Diseases Network, ; Genomics Research to Elucidate the Genetics of Rare Diseases consortium, ; University of Washington Center for Rare Diseases Research, ; Wojcik, M. H.; Beggs, A. H.; Bamshad, M. J.; Wei, C.-L.; Dipple, K. M.; Kumar, R. D.; Blue, E. E.; Jarvik, G.; Chong, J. X.; Witten, D. M.; O'Donnell-Luria, A.; Stergachis, A. B.

2025-11-13 genetic and genomic medicine
10.1101/2025.11.07.25339764 medRxiv
Show abstract

Identifying pathogenic non-coding variants that contribute to Mendelian conditions remains challenging as the functional impact of these variants on gene function is often unknown. We present IsoRanker, a long-read transcriptome sequencing-based framework that prioritizes functionally relevant non-coding variants by detecting genes and novel isoforms with outlier expression, allelic imbalance, and/or nonsense-mediated decay (NMD). We generated paired cycloheximide-treated and untreated fibroblast transcriptomes from 31 individuals (3 individuals with known transcript-altering rare variants and 28 individuals with unsolved conditions) and linked transcripts to phased long-read genomes. IsoRanker successfully recovered known transcript alterations in this cohort and remained robust in subsampling analyses to cohorts of 11 individuals and [~]5 million full-length transcripts per individual. However, performance was dependent upon de novo isoform caller choice, particularly for NMD-sensitive and novel isoforms. Among 28 previously unsolved cases, IsoRanker deprioritized most fibroblast-expressed candidate splice site variants while nominating new leads. In one individual, IsoRanker prioritized HARS1, revealing biallelic non-coding variants that together produced a partial HARS1 loss-of-function and informed targeted therapy in this individual using histidine supplementation. These findings establish long-read, NMD-aware transcriptomics with IsoRanker as an effective approach for generating isoform-level functional evidence, improving classification of non-coding variants and supporting the diagnosis of individuals with rare diseases.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.